Mutation Specific Kinase activity Measurements
Profiling Kinase Conformations
KinCon biolabs is a R&D project of the Institute of Biochemistry at the University of Innsbruck.
We are creating unique biosensors for improved kinase-inhibitor development
Our luciferase based reporter measures drug-driven effects on kinase-activity by reflecting changes of cellular kinase-conformations.
This technology allows reliable profiling of potential kinase-inhibitors under physiological conditions:
- Direct measurement in living cells
- Cancer drug profiling in real-time
- Simple integration of patient mutations for precision medicine
News
Catch up with our latest News
We welcome Philipp Raffeiner who will work on novel Cdk4/6 KinCon reporters in the following months.
With December 1st we started with the execution of proof-of-concept studies to prove the practical suitability and marketability of our KinCon biosensors to accelerate kinase inhibitor development.
KinCon biolabs was selected to receive the ‘FFG Spin-off Fellowship’, a funding Programme by the Austrian Research Promotion Agency (FFG).
Publications
Recent Publications in which the KinCon technology is applied
IUBMB Life, February 2020
DOI: 10.1002/iub.2241
Science Advances, August 2019
DOI: 10.1126/sciadv.aav8463
Contact Us
KinCon biolabs
Institute of Biochemistry
University of Innsbruck
Center for Chemistry and Biomedicine (CCB)
Innrain 80-82
6020 Innsbruck
Austria
Tel.: +43 512 507 57535
info@kincon-biolabs.eu
KinCon biolabs is funded and supported by the University of Innsbruck and the Austrian Research Promotion Agency (FFG)
